Method for in vitro diagnosis or prognosis of testicular cancer

Abstract

The invention relates to a method for in vitro diagnosis or prognosis of testicular cancer which comprises a step of detecting the presence or absence of at least one expression product from at least one nucleic acid sequence selected from the sequences identified in SEQ ID NOS: 1 to 6 or from the sequences which exhibit at least 99% identity with one of the sequences identified in SEQ ID NOS: 1 to 6, to isolated nucleic acid sequences and to the use thereof as a testicular cancer marker.

1 . A method for in vitro diagnosis or prognosis of testicular cancer, in a biological sample from a patient suspected of suffering from testicular cancer, comprising a step of detecting presence or absence of at least one expression product from at least one nucleic acid sequence selected from the full-length sequences identified in SEQ ID NOS: 1 to 6 or from sequences which exhibit at least 99% identity with one of the full-length sequences identified in SEQ ID NOS: 1 to 6. 
     
     
         2 . The method as claimed in  claim 1 , wherein the expression product detected is at least one mRNA transcript or at least one polypeptide. 
     
     
         3 . The method as claimed in  claim 2 , wherein the mRNA transcript is detected by hybridization, by amplification, or by sequencing. 
     
     
         4 . The method as claimed in  claim 1 , wherein the expression product is at least one mRNA transcript, having a sequence selected from one of the full-length sequences identified in SEQ ID NOS: 7 to 12. 
     
     
         5 . The method as claimed in  claim 1 , wherein the mRNA is brought into contact with at least one probe and/or at least one primer under predetermined conditions which enable hybridization, and in that the presence or absence of hybridization to the mRNA is detected. 
     
     
         6 . The method as claimed in  claim 1 , wherein DNA copies of the mRNA are prepared and the DNA copies are brought into contact with at least one probe and/or at least one primer under predetermined conditions which enable hybridization, and in that the presence or absence of hybridization to said DNA copies is detected. 
     
     
         7 . The method as claimed in  claim 2 , wherein the polypeptide expressed is detected by bringing it into contact with at least one binding partner specific for said polypeptide. 
     
     
         8 . A molecular marker for in vitro diagnosis or prognosis of testicular cancer, the molecular marker comprising at least one isolated nucleic acid sequence selected from the group consisting of:
 (i) the full-length DNA sequences set forth in SEQ ID NOS: 1-6,   (ii) the full-length complementary DNA sequences of the sequences defined in   (iii) DNA sequences that exhibit at least 99% identity with the sequences defined in (i) and, or (ii),   (iv) RNA sequences that are the products of transcription of the sequences defined in (i),   (v) RNA sequences that are the products of transcription of sequences that exhibit at least 99% identity with the sequences defined in (i), and   (vi) the full-length RNA sequences set forth in SEQ ID NOS: 7-12.